Elysia Alvarez

Elysia Alvarez

Auto-generated profile, based on publicly available information

Elysia Alvarez

Division of Pediatric Hematology and Oncology, University of California, Davis School of Medicine, Sacramento, CA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in The Lancet Oncology
Verified
Journal Article
Open access
EAElysia M Alvarez
Elysia M Alvarez
LFLisa M Force
Lisa M Force
RXRixing Xu
Rixing Xu
KCKelly Compton
Kelly Compton
DLDan Lu
Dan Lu
NBNickhill Bhakta
Nickhill Bhakta
In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15–39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults. Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15–39 years to define adolescents and young adults. There were 1·19 million (95% UI 1·11–1·28) incident cancer cases and 396 000 (370 000–425 000) deaths due to cancer among people aged 15–39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59·6 [54·5–65·7] per 100 000 person-years) and high-middle SDI countries (53·2 [48·8–57·9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14·2 [12·9–15·6] per 100 000 person-years) and middle SDI (13·6 [12·6–14·8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23·5 million (21·9–25·2) DALYs to the global burden of disease, of which 2·7% (1·9–3·6) came from YLDs and 97·3% (96·4–98·1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally. Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts. Bill & Melinda Gates Foundation, American Lebanese Syrian Associated Charities, St Baldrick's Foundation, and the National Cancer Institute.

20 February 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TKTheresa H.M. Keegan
Theresa H.M. Keegan
RARenata Abrahão
Renata Abrahão
EAElysia M. Alvarez
Elysia M. Alvarez
PURPOSE: Although data from 1975 to 1997 revealed a gap in cancer survival improvement in adolescents and young adults (AYAs; 15-39 years) compared with children and older adults, more recent studies have reported improvements in AYA cancer survival overall. The current analysis provides an update of 5-year relative survival and cancer survival trends among AYAs compared with children and older adults. METHODS: We obtained data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program for 17 regions to obtain recent (2010-2018) 5-year relative survival estimates by cancer type, stage, sex, and race/ethnicity by age group. In addition, we calculated 5-year relative survival trends during 2000-2014. RESULTS: Across 33 common AYA cancers, AYAs and children had high 5-year relative survival (86%) and experienced similar survival improvements over time (average absolute change: AYAs, 0.33%; children 0.36%). Among AYAs, 73% of cancers had improvement in 5-year relative survival since 2000. Despite this overall progress, we identified cancers where survival was worse in AYAs than younger or older patients and cancers that have had either a lack of improvement (osteosarcoma and male breast) or decreases in survival (cervical and female bladder) over time. Furthermore, males had inferior survival to females for all cancers, except Kaposi sarcoma and bladder cancer, and non-Hispanic Black/African American AYAs experienced worse survival than other racial/ethnic groups for many cancers considered in this study. CONCLUSION: Future studies should focus on identifying factors affecting survival disparities by age, sex, and race/ethnicity. Differences in biology, clinical trial enrollment, delivery of treatment according to clinical guidelines, and supportive and long-term survivorship care may account for the survival disparities we observed and warrant further investigation.

27 February 2017 in Cancer
Verified
Journal Article
Closed access
PDF file
EAElysia Alvarez
Elysia Alvarez
TKTheresa Keegan
Theresa Keegan
EJEmily E. Johnston
Emily E. Johnston
RHRobert Haile
Robert Haile
LSLee Sanders
Lee Sanders
LCLisa J. Chamberlain
Lisa J. Chamberlain

19 April 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
EAElysia Alvarez
Elysia Alvarez
MSMidori Seppa
Midori Seppa
SRSilvia Rivas
Silvia Rivas
LFLucia Fuentes
Lucia Fuentes
PVPatricia Valverde
Patricia Valverde
SLSandra Luna‐Fineman
Sandra Luna‐Fineman

22 September 2017 in Cancer
Verified
Journal Article
Closed access
PDF file
EAElysia M. Alvarez
Elysia M. Alvarez
TKTheresa H. Keegan
Theresa H. Keegan
EJEmily E. Johnston
Emily E. Johnston
RHRobert Haile
Robert Haile
LSLee Sanders
Lee Sanders
LCLisa J. Chamberlain
Lisa J. Chamberlain

16 December 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
RARenata Abrahão
Renata Abrahão
EAElysia M. Alvarez
Elysia M. Alvarez
AWAustin R. Waters
Austin R. Waters
CRCrystal C. Romero
Crystal C. Romero
MGMelissa M. Gosdin
Melissa M. Gosdin
TKTheresa H. M. Keegan
Theresa H. M. Keegan